Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
Ann Oncol. 2019 Dec;30(12):1969-1977. doi: 10.1093/annonc/mdz403. Epub 2020 Jan 8.
Ann Oncol. 2019 Dec;30(12):1969-1977. doi: 10.1093/annonc/mdz403. Epub 2020 Jan 8.
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable.
ESMO Open. 2019 May 9;4(2):e000496. doi: 10.1136/esmoopen-2019-000496. eCollection 2019.
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.